[1] WHO. Global hepatitis report, 2017. https://www.who.int/hepatitis/ publications/global-hepatitis-report2017/en/ (accessed April 4, 2019).
[2] Seetharam AB, Perrillo RP,Gish R. Immunosuppression in patients with chronic hepatitis b. Current Hepatitis Reports, 2014,13:235-244.
[3] Lok AS, Zoulim F, Dusheiko G, et al. Hepatitis B cure: From discovery to regulatory approval. J Hepatol, 2017,67:847-861.
[4] Seeger C, Sohn JA. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA. Mol Ther, 2016. 24:1258-1266.
[5] Decorsiere A, Mueller H, Van Breugel PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature, 2016,531:386-389.
[6] Janssen HLA, Brunetto MR, Kim YJ, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol, 2017,68:431-440.
[7] Suresh M, Korolowicz KE, Balarezo M, et al. Antiviral efficacy and host immune response induction during sequential treatment with SB 9200 followed by entecavir in woodchucks. PLoS One, 2017,12:e0169631.
[8] Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol, 2014. 61:1212-1219.
[9] Bertoletti A,Ferrari C. Adaptive immunity in HBV infection. J Hepatol, 2016. 64 (1 Suppl):S71-S83.
[10] Liu J, Zhang E, Ma Z, et al. Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog, 2014,10:e1003856.
[11] Qasim W, Brunetto MR, Gehring AJ, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol, 2015. 62: 486-491. |
